On this page
nystatin
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Nystatin | 500000 [USP'U]/1 | 261178 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Polyene Antifungal [EPC] | EPC | All 12 members |
| Polyenes [CS] | CS | All 13 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 062474-001 | NYSTATIN | TABLET | NYSTATIN | Prescription | AA |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 10 | Manufacturing (CMC) | Approved | November 1, 2012 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | October 29, 1997 | — |
| Supplement | 9 | Labeling | Approved | July 11, 1997 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | December 15, 1993 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | December 15, 1993 | — |
| Original application | 1 | Approved | December 22, 1983 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260805). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Nystatin tablets are contraindicated in patients with a history of hypersensitivity to any of their components.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General . ) Gastrointestinal Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances. Dermatologic Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely. Other Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported. To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei . Its structural formula: C 47 H 75 NO 17 M.W. 926.13 Nystatin tablets are for oral administration and contain 500,000 units of nystatin per tablet. Nystatin tablets contain the inactive ingredients: corn starch, confectioner sugar, dibasic calcium phosphate, FD&C yellow #6, FD&C red #40, FD&C blue # 2, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polysorbate 80, talc and titanium dioxide. Image
Overdosage
openFDA Drug LabelingOVERDOSAGE Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Nystatin Tablets USP, 500,000 Units are round brown, film-coated tablets debossed "HP51" on one side and plain on the other side are packaged in: Bottles of 120: NDC 68788-8690-1 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Manufactured by: Strides Pharma Science Limited Puducherry- 605 014, India. PON/DRUGS/16 13 4193 Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 1041073 Rev: 06/2020 OR Manufactured by: Strides Alathur Private Limited Alathur, Chengalpattu – 603 110, Tamilnadu, India. M.L. No.: TN00002327 Manufactured for: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG(3784) 1049633 Revised: 01/2024 Repackaged By: Preferred Pharmaceuticals Inc. logo Avet logo
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-8350-1 | 63629-8350 | Bryant Ranch Prepack | 28 TABLET, COATED in 1 BOTTLE (63629-8350-1) | April 29, 2022 |
| 63629-8350-2 | 63629-8350 | Bryant Ranch Prepack | 56 TABLET, COATED in 1 BOTTLE (63629-8350-2) | September 2, 2020 |
| 63629-8350-3 | 63629-8350 | Bryant Ranch Prepack | 30 TABLET, COATED in 1 BOTTLE (63629-8350-3) | September 2, 2020 |
| 63629-8350-4 | 63629-8350 | Bryant Ranch Prepack | 120 TABLET, COATED in 1 BOTTLE (63629-8350-4) | June 7, 2024 |
| 23155-051-01 | 23155-051 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 100 TABLET, COATED in 1 BOTTLE (23155-051-01) | October 31, 2011 |
| 68071-3508-9 | 68071-3508 | NuCare Pharmaceuticals,Inc. | 90 TABLET, COATED in 1 BOTTLE (68071-3508-9) | September 20, 2023 |
| 68788-8690-1 | 68788-8690 | Preferred Pharmaceuticals Inc. | 120 TABLET, COATED in 1 BOTTLE (68788-8690-1) | June 7, 2024 |
| 71205-575-30 | 71205-575 | Proficient Rx LP | 30 TABLET, COATED in 1 BOTTLE (71205-575-30) | June 8, 2021 |
| 71205-575-60 | 71205-575 | Proficient Rx LP | 60 TABLET, COATED in 1 BOTTLE (71205-575-60) | June 8, 2021 |
| 71205-575-90 | 71205-575 | Proficient Rx LP | 90 TABLET, COATED in 1 BOTTLE (71205-575-90) | June 8, 2021 |
| 63629-8350 | 63629-8350 | Bryant Ranch Prepack | — | October 31, 2011 |
| 23155-051 | 23155-051 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | — | October 31, 2011 |
| 68071-3508 | 68071-3508 | NuCare Pharmaceuticals,Inc. | — | October 31, 2011 |
| 68788-8690 | 68788-8690 | Preferred Pharmaceuticals Inc. | — | June 7, 2024 |
| 71205-575 | 71205-575 | Proficient Rx LP | — | October 31, 2011 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.